NeoGenomics Launches RaDaR ST MRD Test for HR+/HER2- Breast Cancer (neogenomics.com)

• RaDaR ST detects ctDNA at 1 ppm (LOD95 11 ppm).
• CHiRP study: 100% sensitivity for distant metastases, 16.7 months lead time.
• SURVIVE trial explores ctDNA-guided interventions.

"NeoGenomics announced the tumor-informed molecular residual disease (MRD) test RaDaR ST for HR+/HER2- breast cancer. The test detects circulating tumor DNA (ctDNA) at 1 ppm and demonstrated a median lead time of 16.7 months before clinical recurrence in the CHiRP study, with 100% sensitivity for distant metastatic recurrences."